M&A Deal Summary

Incyte Acquires Escient Pharmaceuticals

On April 23, 2024, Incyte acquired life science company Escient Pharmaceuticals

Acquisition Highlights
  • This is Incyte’s 4th transaction in the Life Science sector.
  • This is Incyte’s 5th transaction in the United States.
  • This is Incyte’s 2nd transaction in California.

M&A Deal Summary
Date 2024-04-23
Target Escient Pharmaceuticals
Sector Life Science
Buyer(s) Incyte
Deal Type Add-on Acquisition
Advisor(s) Centerview Partners
Goldman Sachs (Financial)
Fenwick & West (Legal)

Target

Escient Pharmaceuticals

San Diego, California, United States
Escient Pharmaceuticals is a clinical-stage company that develops novel therapeutics to address various neurosensory-inflammatory disorders. The company’s pipeline includes two first-in-class small molecule antagonists targeting MRGPRX2 for treating various mast cell-mediated disorders and MRGPRX4 for cholestatic pruritus. Escient Pharmaceuticals is based in San Diego, California.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Incyte

Wilmington, Delaware, United States
Category Company
Founded 1991
Sector Life Science
Employees2,524
Revenue 3.7B USD (2023)
DESCRIPTION

Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. Incyte was founded in 1991 and is based in Wilmington, Delaware.

DEAL STATS #
Overall 5 of 5
Sector (Life Science) 4 of 4
Type (Add-on Acquisition) 4 of 4
State (California) 2 of 2
Country (United States) 5 of 5
Year (2024) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-10-03 Villaris

Cary, North Carolina, United States

Villaris is an asset-centric biopharmaceutical company that developed a potentially transformational new treatment to improve the lives of people living with vitiligo. Villaris was formed in 2019 and is based in Cary, North Carolina.

Buy $1.4B
Mergr

Product

Company

Legal